RLMD
Relmada Therapeutics, Inc. [RLMD] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
RLMD Stock Summary
In the News
RLMD Financial details
Company Rating
-
Market Cap
140.31M
Income
-98.79M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
20
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-0.94
Forward P/E
-
PEG
0.25
P/S
-
P/B
1.02
P/C
-
P/FCF
-1.33
Quick Ratio
12.62
Current Ratio
12.95
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.28
EPS next Y
-
EPS next Q
-
EPS this Y
-38.11%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
15.07%
-
-
-
-
SMA20
4.92%
SMA50
39.13%
SMA100
137.04%
Inst Own
-
Inst Trans
-
ROA
-100%
ROE
-91%
ROC
-1.15%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.36-7.223
52W High
-91.57%
52W Low
-70.48%
RSI
44.68
Rel Volume
1.5
Avg Volume
218.83K
Volume
328.1K
Perf Week
-17.89%
Perf Month
-15.65%
Perf Quarter
91.01%
Perf Half Y
69.17%
-
-
-
-
Beta
0.191
-
-
Volatility
0.02%, 0.03%
Prev Close
-5.14%
Price
0.5904
Change
-7.46%
Company Profile
- Volume Average 218.83K
- Market Capitalization 140.31M
- Employee 20
- CEO Dr. Sergio Traversa M.B.A., Pharm.D.
- Headquarters Coral Gables,FL,US
- IPO Date 2014-06-20
-
Website
https://www.relmada.com 
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
